Sign in

You're signed outSign in or to get full access.

HB

HARVARD BIOSCIENCE INC (HBIO)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 2025 revenue was $20.5M and gross margin 56.4%, beating both company guidance ($18–$20M; 55–57%) and Wall Street revenue consensus ($18.75M*) on improved China shipments post-tariff clarity; GAAP diluted EPS was $(0.05) while diluted adjusted EPS was $(0.01) . Revenue consensus mean for Q2 2025: $18.75M*; Primary EPS consensus mean: $(0.025)*.
  • Sequentially, revenue declined 6% (to $20.5M from $21.8M) but gross margin expanded 40 bps, driven by manufacturing actions and lower OpEx; adjusted EBITDA improved to $1.5M vs $1.3M in Q2’24 .
  • Operating cash flow was strong at $2.8M in Q2 and $5.7M YTD, with net debt reduced to $27.9M; the company amended its credit facility to extend the refinance deadline to Dec 5 and waived certain covenants for Q3, with a 700 bps SOFR adder and 100 bps amendment fee .
  • Q3 2025 guidance: revenue $19–$21M and gross margin 56–58%, supported by a strong start to orders; management emphasized cost discipline, product adoption (SoHo telemetry, VivaMARS, MeshMEA organoids), and balance sheet refinancing as strategic priorities .

What Went Well and What Went Wrong

  • What Went Well

    • Beat revenue guidance on higher China shipments; gross margin towards the high end of guided range (56.4%) .
    • OpEx down ~$2M YoY, yielding adjusted operating income of $1.0M and adjusted EBITDA of $1.5M despite lower revenue .
    • CEO highlighted “accelerate product adoption” with milestones: SoHo telemetry expansion, VivaMARS pilot at LabCorp, ~$1M BTX consumables from a large customer, and growing MeshMEA organoid adoption; “Our priorities are to grow our core business and re-structure our balance sheet” .

  • What Went Wrong

    • Revenue down 11% YoY due to NIH budget clarity delays impacting US academic demand; APAC down >25% sequentially and YoY amid tariff uncertainty .
    • Gross margin down 80 bps YoY from 57.2% to 56.4% on lower fixed cost absorption .
    • Credit costs increased: SOFR adder +700 bps and 100 bps fee under the amendment; debt maturity pressure necessitates refinance by Dec 5 .

Financial Results

MetricQ4 2024Q1 2025Q2 2025
Revenue ($USD Millions)$24.556 $21.774 $20.450
GAAP Diluted EPS ($USD)$0.00 $(1.14) $(0.05)
Diluted Adjusted EPS ($USD)$0.06 $(0.01) $(0.01)
Gross Margin (%)57.1% 56.0% 56.4%
Adjusted Operating Margin (%)10.1% 1.5% 5.1%
Adjusted EBITDA ($USD Millions)$3.0 $0.8 $1.5

Results vs estimates (Wall Street consensus, S&P Global):

MetricQ4 2024Q1 2025Q2 2025
Revenue Consensus Mean ($USD)$24.150M*$19.200M*$18.750M*
Primary EPS Consensus Mean ($USD)$0.05*$(0.04)*$(0.025)*
Actual Revenue ($USD)$24.556M $21.774M $20.450M
Actual Primary EPS ($USD)$0.06*$(0.01)*$(0.01)*

Values retrieved from S&P Global.*

Regional performance (Q2 2025):

RegionSequential Change (Q2 vs Q1)YoY Change (vs Q2 2024)
Americas−5.4% −11.7%
Europe+9% ~Flat
APAC (incl. China)>−25% >−25%

Key KPIs and Balance Sheet

KPIQ4 2024Q1 2025Q2 2025
Cash from Operations ($USD Millions)$1.7 $3.0 $2.8
Debt ($USD Millions)$36.956 $35.958 $34.864
Net Debt ($USD Millions)$33.242 $30.804 $27.908
Cash & Equivalents ($USD Millions)$4.108 $5.546 $7.442
Accounts Receivable, net ($USD Millions)$14.866 $13.479 $11.937
Inventories ($USD Millions)$23.245 $22.816 $22.255

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueQ2 2025$18–$20M Actual $20.5M Beat guidance
Gross MarginQ2 202555–57% Actual 56.4% In range
RevenueQ3 2025N/A$19–$21M New
Gross MarginQ3 2025N/A56–58% New
Covenants (Credit)Q3 2025Leverage/fixed coverage testedWaived (except min liquidity $3M) Amended

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4 2024, Q1 2025)Current Period (Q2 2025)Trend
NIH funding and academic demandQ4: US academic “end-of-year bump” absent; exposure ~half of business is academic, NIH ~30% of US academic revenue . Q1: cycles extended; budgets exist; softness guided into Q2 .NIH delays continue to extend cycles; budgets remain; improvement expected into 2026 .Stabilizing over time; improvement expected medium term
Tariffs (China/Europe)Q1: China softening post-April tariffs; APAC challenged; APAC sequential up; guided caution .APAC >25% down seq/YoY; China shipments halted in April, resumed after tentative 10% tariff; Europe tariffs ~15% with volatility .Clarity improving; worst may be behind; monitoring EU volatility
Product adoption (SoHo, VivaMARS, MeshMEA)Q4/Q1: Strong interest; SoHo expansion; VivaMARS LabCorp pilot; MeshMEA early adopters (Stanford, Mayo; NIH purchase) .SoHo shipments adding cardiac/neuro; VivaMARS pilot progresses; MeshMEA adoption expands; regulatory NAMs tailwind .Positive momentum; structural tailwinds
Capital structure & refinancingQ4: required refinance by June 30; engaged bankers . Q1: multiple proposals; in negotiation .Amendment extends to Dec 5; covenants largely waived in Q3; SOFR adder +700 bps; 100 bps fee .De-risked timing; cost of debt higher
ERP consolidationQ4: US ERP consolidation; near-term inefficiencies, expected margin/inventory benefits .Continued focus on cost and operational discipline .Execution ongoing; margin discipline maintained

Management Commentary

  • “Our priorities are to grow our core business and re-structure our balance sheet… position us well for revenue growth and margin expansion in 2026 and beyond.” — John Duke, President & CEO .
  • “We are guiding to $19–$21M of revenue and 56–58% gross margin [for Q3], reflecting continued financial discipline.” — Mark Frost, Interim CFO .
  • “Orders and shipments [in China] halted in April, but gradually returned to more normal behavior after the tentative agreement of a 10% tariff level.” — Mark Frost .
  • “We progressed our VivaMARS automation pilot with LabCorp… achieved a key milestone in BTX bioproduction with $1M in consumable revenue… continue to expand adoption of our MeshMEA organoid platform.” — John Duke .

Q&A Highlights

  • Debt/refinance: Company expects debt near ~$33M by Dec 5 as $1M/quarter amortization continues; terms likely “BB/Single-B type” pricing; amendment waives certain covenants in Q3 .
  • NIH outlook: Purchasing cycles extended; budgets intact; improved funding in 2026 would benefit neuroscience/MEA organoid platforms .
  • China and tariffs: China ~10% of revenue; April pause in shipments; resumed under ~10% tariff; Europe tariff environment cited at ~15% with volatility; potential country-of-origin flexibility via European ops .
  • Organoid publications: Expect updates at Society for Neuroscience in November, supporting academic validation .

Estimates Context

  • Q2 2025: Revenue $20.45M beat consensus $18.75M*; Primary EPS GAAP vs S&P Primary EPS: GAAP diluted loss $(0.05) , S&P Primary EPS actual $(0.01)* vs consensus $(0.025)*, and company diluted adjusted EPS $(0.01) .
  • Prior quarters: Q1 2025 revenue $21.77M beat $19.20M*; Primary EPS actual $(0.01)* ahead of $(0.04); Q4 2024 revenue $24.56M modestly beat $24.15M; Primary EPS $0.06* beat $0.05*. Values retrieved from S&P Global.*

Key Takeaways for Investors

  • Q2 revenue and margin execution outperformed guidance and consensus as China activity normalized and cost actions offset lower volume; this is supportive of near-term upside vs expectations . Values retrieved from S&P Global.*
  • The amendment de-risks near-term liquidity and covenant pressure, but increases cost of debt; successful refinance remains a pivotal H2’25 catalyst .
  • Product catalysts are credible: SoHo telemetry expansion, VivaMARS CRO automation, BTX bioproduction consumables, and MeshMEA aligned with NAMs regulatory tailwinds — underpinning a 2026 growth narrative .
  • Academic demand headwinds (NIH delays) persist but budgets intact; watch for 2026 funding resolution and organoid publication momentum to accelerate adoption .
  • Regional volatility (EU tariffs, China) remains a risk; management cited flexibility in country-of-origin to mitigate impacts; APAC trends improving from April trough .
  • Strong cash generation and working capital improvements lowered net debt; continued $1M/quarter amortization benefits leverage ahead of refinance .
  • Near term, focus on Q3 print vs $19–$21M revenue and 56–58% GM guidance; any upside from China shipments or academic demand stabilization could be a positive surprise .

Sources

  • Q2 2025 press release and financials .
  • Q2 2025 8-K and exhibit .
  • Q2 2025 earnings call transcript .
  • CEO succession PR (Q2 context and preliminary outlook) .
  • Q1 2025 press release and call (trend analysis) .
  • Q4 2024 press release and call (trend analysis) .

Values retrieved from S&P Global.*